Syndax Pharmaceuticals (SNDX) Other Gross PP&E Adjustments (2016 - 2026)
Syndax Pharmaceuticals (SNDX) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with -$30.2 million as the latest value for Q1 2026.
- For Q1 2026, Other Gross PP&E Adjustments fell 939.0% year-over-year to -$30.2 million; the TTM value through Mar 2026 reached -$30.2 million, down 939.0%, while the annual FY2025 figure was -$26.3 million, 1220.52% down from the prior year.
- Other Gross PP&E Adjustments hit -$30.2 million in Q1 2026 for Syndax Pharmaceuticals, down from -$26.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$1.3 million in Q2 2022 and bottomed at -$30.2 million in Q1 2026.
- Average Other Gross PP&E Adjustments over 5 years is -$5.2 million, with a median of -$2.0 million recorded in 2024.
- Year-over-year, Other Gross PP&E Adjustments soared 58.57% in 2024 and then tumbled 1220.52% in 2025.
- Syndax Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.0 million in 2022, then fell by 27.69% to -$2.5 million in 2023, then rose by 21.05% to -$2.0 million in 2024, then crashed by 1220.52% to -$26.3 million in 2025, then decreased by 15.17% to -$30.2 million in 2026.
- According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$30.2 million, -$26.3 million, and -$1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.